Form 4: uniQure Director Jeremy Springhorn Equity Update

Director Jeremy Springhorn received restricted share units and stock options while selling shares to cover tax obligations.

Summary

• Director Jeremy P. Springhorn was granted 7,550 restricted share units (RSUs) on June 10, 2026.
• The director was granted 13,980 stock options with an exercise price of $26.82 on June 10, 2026.
• A total of 1,993 shares were sold on June 11, 2026, at a weighted average price of $27.06 to satisfy tax withholding obligations related to RSU vesting.
• Following these transactions, the director holds 43,251 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and tax compliance.

Positives

• Director maintains a significant equity stake of 43,251 shares in the company.
• Equity grants align the director's interests with long-term shareholder value through vesting requirements.

Negatives

• The sale of 1,993 shares, while for tax purposes, reduces the total direct holdings of the director.

Risks

• Vesting of equity awards is contingent upon the director's continued relationship with the issuer.
• Stock options are subject to market volatility and may not be profitable if the share price remains below the $26.82 exercise price.

Future Outlook

The equity grants vest 100% on the first anniversary of the grant date, June 10, 2027, provided the director maintains their relationship with the company.

Industry Context

StockSavvy.ai notes that routine equity grants and tax-related sales by directors are standard corporate governance practices in the biotechnology sector, reflecting typical compensation structures rather than shifts in strategic outlook.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice among publicly traded biotech firms to manage executive tax liabilities.
• The one-year cliff vesting schedule for director equity is consistent with industry norms for retention and alignment.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were primarily related to tax obligations and standard compensation.

Next Steps

• Vesting of restricted share units on June 10, 2027.
• Vesting of stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, Form 4, Insider Trading, Equity Compensation, Biotech